Given that the changes in B cells within the bone marrow during the early AD stages in mice are dominated by an increase in ABCs (Fig. 3e) and that IL-6 is essential for the Aβ-induced upregulation of ABCs (Fig. 4h, i), we treated AD model mice with the IL-6R inhibitor tocilizumab rather than the traditional approach of depleting all B cells with an anti-CD20 antibody. Here, IL6R is linked to Alzheimer disease.